Adenovirus vectors activate Vδ2+ γδT cells in a type I interferon-, TNF-, and IL-18-dependent manner

Nicholas M. Provine; Ali Amini; Lucy C. Garner; Michael E.B. FitzPatrick; Christina Dold; Laura Silva Reyes; Senthil Chinnakannan; Blanche Oguti; Meriel Raymond; Fulvia Troise; Stefania Capone; Antonella Folgori; Eleanor Barnes; Christine S. Rollier; Andrew J. Pollard; Paul Klenerman

doi:10.1002/eji.202149367

Adenovirus vectors activate Vδ2⁺ γδT cells in a type I interferon-, TNF-, and IL-18-dependent manner

Nicholas M. Provine^*, Ali Amini, Lucy C. Garner, Michael E.B. FitzPatrick, Christina Dold, Laura Silva Reyes, Senthil Chinnakannan, Blanche Oguti, Meriel Raymond, Fulvia Troise, Stefania Capone, Antonella Folgori, Eleanor Barnes, Christine S. Rollier, Andrew J. Pollard, Paul Klenerman^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

4 Citations (Scopus)

Original language	English
Pages (from-to)	835-837
Number of pages	3
Journal	European Journal of Immunology
Volume	52
Issue number	5
DOIs	https://doi.org/10.1002/eji.202149367
Publication status	Published - May 2022
Externally published	Yes

Bibliographical note

Funding Information:
We thank Hussein Al‐Mossawi and ImCheck Therapeutics for reagents and the trial volunteers. The authors received funding from the following organizations: N.M.P. (Oxford‐UCB Postdoctoral Fellowship); A.A. (Wellcome [216417/Z/19/Z]); L.C.G. (Wellcome [109028/Z/15/Z]); M.E.B.F. (Oxford‐Celgene Doctoral Fellowship). E.B. [MRC (STOP‐HCV and MR/R014485/1), NIHR Senior Investigator, NIHR BRC]; C.S.R. (NIHR BRC); A.J.P. (NIHR Senior Investigator); P.K. (Wellcome [WT109965MA], NIHR Senior Investigator). The ChAdOx1 MenB.1 trial is funded by the MRC DPFS (MRM0076931). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

Access to Document

10.1002/eji.202149367

Cite this

Provine, N. M., Amini, A., Garner, L. C., FitzPatrick, M. E. B., Dold, C., Silva Reyes, L., Chinnakannan, S., Oguti, B., Raymond, M., Troise, F., Capone, S., Folgori, A., Barnes, E., Rollier, C. S., Pollard, A. J., & Klenerman, P. (2022). Adenovirus vectors activate Vδ2⁺ γδT cells in a type I interferon-, TNF-, and IL-18-dependent manner. European Journal of Immunology, 52(5), 835-837. https://doi.org/10.1002/eji.202149367

@article{f35ff9ee27aa4efd9dd13ea91f1072e3,

title = "Adenovirus vectors activate Vδ2+ γδT cells in a type I interferon-, TNF-, and IL-18-dependent manner",

author = "Provine, {Nicholas M.} and Ali Amini and Garner, {Lucy C.} and FitzPatrick, {Michael E.B.} and Christina Dold and {Silva Reyes}, Laura and Senthil Chinnakannan and Blanche Oguti and Meriel Raymond and Fulvia Troise and Stefania Capone and Antonella Folgori and Eleanor Barnes and Rollier, {Christine S.} and Pollard, {Andrew J.} and Paul Klenerman",

note = "Funding Information: We thank Hussein Al‐Mossawi and ImCheck Therapeutics for reagents and the trial volunteers. The authors received funding from the following organizations: N.M.P. (Oxford‐UCB Postdoctoral Fellowship); A.A. (Wellcome [216417/Z/19/Z]); L.C.G. (Wellcome [109028/Z/15/Z]); M.E.B.F. (Oxford‐Celgene Doctoral Fellowship). E.B. [MRC (STOP‐HCV and MR/R014485/1), NIHR Senior Investigator, NIHR BRC]; C.S.R. (NIHR BRC); A.J.P. (NIHR Senior Investigator); P.K. (Wellcome [WT109965MA], NIHR Senior Investigator). The ChAdOx1 MenB.1 trial is funded by the MRC DPFS (MRM0076931). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. ",

year = "2022",

month = may,

doi = "10.1002/eji.202149367",

language = "English",

volume = "52",

pages = "835--837",

journal = "European Journal of Immunology",

issn = "0014-2980",

publisher = "Wiley-VCH Verlag",

number = "5",

}

Provine, NM, Amini, A, Garner, LC, FitzPatrick, MEB, Dold, C, Silva Reyes, L, Chinnakannan, S, Oguti, B, Raymond, M, Troise, F, Capone, S, Folgori, A, Barnes, E, Rollier, CS, Pollard, AJ & Klenerman, P 2022, 'Adenovirus vectors activate Vδ2⁺ γδT cells in a type I interferon-, TNF-, and IL-18-dependent manner', European Journal of Immunology, vol. 52, no. 5, pp. 835-837. https://doi.org/10.1002/eji.202149367

TY - JOUR

T1 - Adenovirus vectors activate Vδ2+ γδT cells in a type I interferon-, TNF-, and IL-18-dependent manner

AU - Provine, Nicholas M.

AU - Amini, Ali

AU - Garner, Lucy C.

AU - FitzPatrick, Michael E.B.

AU - Dold, Christina

AU - Silva Reyes, Laura

AU - Chinnakannan, Senthil

AU - Oguti, Blanche

AU - Raymond, Meriel

AU - Troise, Fulvia

AU - Capone, Stefania

AU - Folgori, Antonella

AU - Barnes, Eleanor

AU - Rollier, Christine S.

AU - Pollard, Andrew J.

AU - Klenerman, Paul

N1 - Funding Information: We thank Hussein Al‐Mossawi and ImCheck Therapeutics for reagents and the trial volunteers. The authors received funding from the following organizations: N.M.P. (Oxford‐UCB Postdoctoral Fellowship); A.A. (Wellcome [216417/Z/19/Z]); L.C.G. (Wellcome [109028/Z/15/Z]); M.E.B.F. (Oxford‐Celgene Doctoral Fellowship). E.B. [MRC (STOP‐HCV and MR/R014485/1), NIHR Senior Investigator, NIHR BRC]; C.S.R. (NIHR BRC); A.J.P. (NIHR Senior Investigator); P.K. (Wellcome [WT109965MA], NIHR Senior Investigator). The ChAdOx1 MenB.1 trial is funded by the MRC DPFS (MRM0076931). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

PY - 2022/5

Y1 - 2022/5

UR - http://www.scopus.com/inward/record.url?scp=85122968638&partnerID=8YFLogxK

U2 - 10.1002/eji.202149367

DO - 10.1002/eji.202149367

M3 - Comment/debate

C2 - 34958459

AN - SCOPUS:85122968638

SN - 0014-2980

VL - 52

SP - 835

EP - 837

JO - European Journal of Immunology

JF - European Journal of Immunology

IS - 5

ER -

Adenovirus vectors activate Vδ2+ γδT cells in a type I interferon-, TNF-, and IL-18-dependent manner

Bibliographical note

Access to Document

Other files and links

Cite this

Adenovirus vectors activate Vδ2⁺ γδT cells in a type I interferon-, TNF-, and IL-18-dependent manner